SGMO - Sangamo Therapeutics, Inc.
| Previous Close | 11.70 |
| Open | 11.70 |
| Bid | 11.66 x 1200 |
| Ask | 11.67 x 800 |
| Day's Range | 11.48 - 11.82 |
| 52 Week Range | 6.26 - 19.25 |
| Volume | 472,681 |
| Avg. Volume | 2,549,117 |
| Market Cap | 1.343B |
| Beta (3Y Monthly) | 1.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.70 |
| Earnings Date | May 6, 2019 - May 10, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.20 |
- PR Newswire•7 days ago
Sangamo Therapeutics Announces Presentations At 2019 Annual Meeting Of The American Society Of Gene & Cell Therapy
BRISBANE, Calif. , April 15, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced that Sangamo scientists and collaborators will present data from ...
Market Realist•14 days agoWhat’s Expected for Sangamo’s and Amarin’s EPS
How Sangamo Therapeutics and Amarin Compare(Continued from Prior Part)Expense guidance In its fourth-quarter earnings presentation, Sangamo Therapeutics (SGMO) guided for operating expenses of $210 million–$220 million in fiscal 2019. At the end of
Market Realist•14 days agoComparing Sangamo’s and Amarin’s Revenue Growth
How Sangamo Therapeutics and Amarin Compare(Continued from Prior Part)Growth strategy In its fourth-quarter earnings presentation, Sangamo Therapeutics (SGMO) highlighted its focus on developing innovative genomic medicines targeting conditions in
- PR Newswire•14 days ago
Sangamo Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
RICHMOND, Calif., April 8, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) today announced the completion of its previously announced underwritten public offering of 12,650,000 shares of its common stock at a price to the public of $11.50 per share, including 1,650,000 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares. All of the shares were sold by Sangamo. Including the option exercise, the aggregate gross proceeds to Sangamo from the offering, before deducting the underwriting discounts and commissions and offering expenses, were approximately $145.5 million.
- MoneyShow•17 days ago
Sangamo- Biotech "Fires on All Cylinders"
Sangamo Therapeutics (SGMO) has delivered excellent news across their proprietary ZFN drug development platform, asserts biotech expert John McCamant, editor of The Medical Technology Stock Letter.
- PR Newswire•18 days ago
Sangamo Therapeutics Announces Pricing of Public Offering of Common Stock
RICHMOND, Calif., April 4, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $11.50 per share. All of the shares are being sold by Sangamo. The gross proceeds to Sangamo from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $126.5 million.
- Benzinga•18 days ago
The Daily Biotech Pulse: Recro Restructures, Biotechs Raise Proceeds In Droves, Silk Road, NGM Biopharma To Debut
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 3) Denali Therapeutics Inc (NASDAQ: DNLI ) GALAPAGOS NV/S ...
- PR Newswire•19 days ago
Sangamo Therapeutics Announces Proposed Public Offering of Common Stock
RICHMOND, Calif., April 3, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares are being offered by Sangamo. In addition, Sangamo expects to grant the underwriters of the offering a 30-day option to purchase additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.
- Zacks•19 days ago
Sangamo Rises on Positive Phase I/II Hemophilia Study Data
Sangamo (SGMO) and partner Pfizer announce encouraging data from a phase I/II study evaluating their gene therapy candidate for treating hemophilia A.
- Motley Fool•19 days ago
Does Sangamo Have the Best Gene Therapy Program Now?
The grandaddy of gene-editing stocks recently provided an encouraging update, but it isn't the only experimental hemophilia therapy out there.
- InvestorPlace•19 days ago
3 Big Stock Charts for Wednesday: Twitter, Western Union and Wynn Resorts
The bulls tried to follow through on Monday's impressive bullishness, but just couldn't make it happen. After spending some time above and below the previous day's close, the S&P 500 ended yesterday's action at 2,867.24, effectively even with Monday's last trade.Sangamo Therapeutics (NASDAQ:SGMO) did all that it could do to get the market off the fence, gaining 29% on the heels of news that its hemophilia drug SB-525, co-developed with Pfizer (NYSE:PFE), showed tremendous promise in early stage trials.At the other end of the spectrum, Walgreens Boots Alliance (NASDAQ:WBA) was off nearly 13% after missing second-quarter estimates and subsequently dialing back its full-year earnings outlook. Instead of growing the bottom line between 7% and 12%, the drugstore chain now expects earnings to be flat. CVS Health (NYSE:CVS) fell in sympathy, though not as dramatically.InvestorPlace - Stock Market News, Stock Advice & Trading TipsNone of those names are well-suited for trading headed into today's session, however. Rather, it's the stock charts of Western Union (NYSE:WU), Wynn Resorts (NASDAQ:WYNN) and Twitter (NYSE:TWTR) that offer the most promise. Here's why, and what to look for. Wynn Resorts (WYNN)Wynn Resorts, like most other casino stocks, suffered a worse-than-average 2018. At times things have looked different -- and better -- so far this year, but WYNN stock was never firmly out of the woods… * The 8 Best Stocks to Buy for an April Rally … perhaps until yesterday. Though far from being the ideal effort, Wynn Resorts stock has broken above three key resistance lines that make it easier and more likely to continue higher. Click to Enlarge • One of those resistance lines is the $134.10 area, marked in yellow on the daily chart, while the other is the 200-day moving average line plotted in white on both stock charts. The third? The 38.2% Fibonacci retracement line only marked on the weekly chart.• The big flaw in the move is that a gap was left behind with Monday's bullish open. The bears (and bulls, for that matter) may try to go back and fill it in.• Even if the gap is filled, a renewal of the bullish effort would still be easier to muster after Tuesday's incremental progress.• The most plausible upside targets here are the horizontal resistance made in July, around $167.50, and the 61.8% Fibonacci retracement line at $160. Twitter (TWTR)Twitter hasn't made any net progress since its big plunge last July. That has been good and bad, in that shares also weren't crushed during the fourth quarter of last year when most stocks were thumped.There has been effective progress being made, though, which quietly started to come to fruition as of Tuesday. While not perfect, the bulls may have just tipped their hand. Click to Enlarge • The sideways trading range framed in red lines on both stock charts has since been replaced by a converging wedge pattern marked by yellow lines. The stock pushed above the upper boundary of that wedge shape yesterday.• At the same time, Tuesday's modest gain was still enough to push TWTR shares back above the 200-day moving average line plotted in white on both stock charts.• Though the congestion gives Twitter shares time to build up steam to stage a breakout, there has been an alarming lack of volume behind the effort -- bearish or bullish -- thus far.• Even if yesterday's effort gains traction, the big catalyst is still a move above the horizontal ceiling around $36. Western Union (WU)Finally, Western Union shares have been on a tear since late-December but made huge technical progress earlier this week and late last week. With some momentum now behind it, WU stock appears ready to roll higher, though its plausible ceiling has also been well defined and doesn't leave a ton of room for a big move higher. Click to Enlarge • The daily chart illustrates two key technical events. One of them is the move above the 200-day moving average, marked in white on both stock charts. The other is a break above the falling resistance line that has led to lower highs since October, marked in red on the daily chart.• Unlike many other stocks making forward progress right now, there's some volume behind the effort. This is evident in the growing green volume bars on the daily chart, but also indicated by the Chaikin line's cross back above zero for the weekly chart.• Though this breakout thrust looks healthy, there's something about the $23 area that has been a problem in the past. Even if for purely psychological reasons, any rally effort should be monitored if and when it reaches that mark.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Best ETFs for 2019: A Close Race at the Front * 15 Stocks to Buy Leading the Financial Charge * 7 Stocks From Around the World That Beat U.S. Stocks Compare Brokers The post 3 Big Stock Charts for Wednesday: Twitter, Western Union and Wynn Resorts appeared first on InvestorPlace.
- Motley Fool•20 days ago
Why Delta Air Lines, Sangamo Therapeutics, and Grayscale Bitcoin Trust Jumped Today
Some investments stood out on a quiet day for the market.
- Investor's Business Daily•20 days ago
Gene-Focused Biotechs Pop After Pfizer Partner Scores In Hemophilia A
Sangamo Therapeutics popped to a five-month high Tuesday after its gene therapy showed promise as a hemophilia A treatment. Sangamo stock jumped by double digits in high volume.
- Benzinga•20 days ago
Sangamo Soars Amid Multiple Development Pipeline Updates
Interim data from the Phase 1/2 Alta study evaluating Sangamo's investigational SB-525 gene therapy for severe hemophilia A showed that it was well-tolerated and demonstrated a dose-dependent increase in Factor VIII levels across the four dosage cohorts.
- Schaeffer's Investment Research•20 days ago
Sangamo Therapeutics Bull Gap Fuels Hot Options Trading
SGMO stock is headed toward its best day since May 2017
- InvestorPlace•20 days ago
Sangamo Therapeutics News: Why SGMO Stock Is Soaring Today
A bevy of Sangamo Therapeutics news for Tuesday has SGMO stock flying high today.Source: Shutterstock Sangamo Therapeutics (NASDAQ:SGMO) starts off the day by announcing a new deal to increase its manufacturing capacity. The company signed a deal with Brammer Bio that will give it access to access to large-scale AAV manufacturing. This includes up to 2000-L bioreactor scale for manufacturing of its drug.To go along with this Sangamo Therapeutics news is additional manufacturing at one of its plants in Brisbane, Calif. This is for a Phase 1/2 cGMP manufacturing facility that it expects to be up and running in 2020.InvestorPlace - Stock Market News, Stock Advice & Trading TipsOther Sangamo Therapeutics news that has SGMO stock up today has to do with interim results from a recent study. This study is for its SB-525 gene therapy treatment for severe hemophilia A. The company notes that the drug was well-received by patients. This includes strong tolerability and an increase in Factor VIII levels.More Sangamo Therapeutics news today about studies includes one for its ST-400. This is an autologous cell therapy that involves gene editing of a patient's own hematopoietic stem cells. The company notes that there was a serious adverse event at the start of the trial, but that the treatment's results were promising afterwards. * 15 Stocks to Buy Leading the Financial Charge "These initial results are especially encouraging given the patient's β0/ β0 genotype, a patient population which has proved to be difficult-to-treat and where there is high unmet medical need," Angela Smith, MD, Associate Professor in the Division of Pediatric Blood and Marrow Transplantation at the University of Minnesota, said in a statement.SGMO stock was up 29% as of Tuesday morning. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks From Around the World That Beat U.S. Stocks * 7 Breakout Stocks to Watch in 2019 * 5 Cheap Small-Cap Stocks to Buy As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Sangamo Therapeutics News: Why SGMO Stock Is Soaring Today appeared first on InvestorPlace.
- Motley Fool•20 days ago
Why Sangamo Therapeutics Stock Is Soaring Today
Promising early clinical data has investors excited about Sangamo's hemophilia A gene therapy.
- TheStreet.com•20 days ago
Sangamo Stock Soars on Positive Hemophilia Treatment Trial
The company announced in a press release that its SB-525 developed with Pfizer was "generally well tolerated and demonstrated a dose-dependent increase in Factor VIII levels across the four dosage cohorts. "These interim results suggest that SB-525 may be well-tolerated and may prove to have the predictability and sustained treatment effect that can bring clinical benefit in patients with hemophilia A," Sangamo Chief Medical Officer Edward Conner said in a statement. Separately, Sangamo announced that early data for another gene-editing therapy called ST-400, developed in partnership with pharmaceutical company Sanofi, were also progressing well.
- MarketWatch•20 days ago
Sangamo's stock soars after upbeat trial data for hemophilia treatment
Shares of Sangamo Therapeutics Inc. soared 27% in premarket trade Tuesday, after the genomic medicine company and Pfizer Inc. announced "encouraging" results from a phase 1/2 study of SB-525 gene therapy for the treatment of severe hemophilia A. Pfizer's stock was still inactive ahead of the open. The companies said SB-525 was generally well tolerated and demonstrated a dose-dependent increase in Factor VIII levels across the four dosage cohorts. Based on the study's results, the Safety Monitoring Committee (SMC) recommended expansion at a specific dose. "These interim results suggest that SB-525 may be well-tolerated and may prove to have the predictability and sustained treatment effect that can bring clinical benefit in patients with hemophilia A," said Sangamo Chief Medical Officer Edward Conner. Sangamo's stock has tumbled 17.0% year to date through Monday and Pfizer shares have slipped 1.9%, while the Dow Jones Industrial Average has climbed 12.6%.
- Business Wire•20 days ago
Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy
Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, and Pfizer, Inc. (PFE) today announced interim data from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A. Data indicate that SB-525 was generally well-tolerated and demonstrated a dose-dependent increase in Factor VIII (FVIII) levels across the four dosage cohorts. Eight patients total were dosed.
- PR Newswire•20 days ago
Sangamo and Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy
BRISBANE, Calif. and NEW YORK, April 2, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, and Pfizer, Inc. (PFE) today announced interim data from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A. Data indicate that SB-525 was generally well-tolerated and demonstrated a dose-dependent increase in Factor VIII (FVIII) levels across the four dosage cohorts. Eight patients total were dosed.
- PR Newswire•20 days ago
Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data
BRISBANE, Calif., April 2, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, today announced recent progress across its clinical portfolio, including early data for ST-400, an ex vivo gene-edited beta thalassemia cell therapy developed in partnership with Sanofi, and next steps for its in vivo genome editing programs. Additionally, in separate announcements, Sangamo today also provided an update on its AAV manufacturing capacity and capabilities, and in a joint press release with partner Pfizer, reported interim data from the SB-525 hemophilia A gene therapy program. "Over the last three years, we've built a solid foundation to support Sangamo's clinical organization and we believe this morning's updates demonstrate how the various components of our clinical development activities are coming together," said Sandy Macrae, Sangamo's Chief Executive Officer.
- PR Newswire•20 days ago
Sangamo Announces Agreement Securing Access To Large-Scale, Commercial-Grade Manufacturing Capacity At Brammer Bio
BRISBANE, Calif., April 2, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, today announced it has signed an option agreement with Brammer Bio, a gene therapy contract development and manufacturing organization, to secure access to large-scale AAV manufacturing. Additionally, at Sangamo's new facilities in Brisbane, California, construction is underway of a Phase 1/2 cGMP manufacturing facility, which is expected to be operational in 2020.
- PR Newswire•21 days ago
Sangamo Therapeutics To Host April 2, 2019 Conference Call To Provide Clinical Update
BRISBANE, Calif., April 1, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will host a conference call on Tuesday, April 2 nd ...
